Possibilities of interstitial photodynamic therapy in the treatment of brain glioblastoma DOI Creative Commons
A. Yu. Rynda,

V. E. Olyushin,

Д. М. Ростовцев

et al.

Biomedical Photonics, Journal Year: 2025, Volume and Issue: 14(1), P. 4 - 19

Published: April 16, 2025

Interstitial photodynamic therapy (iPDT) is a minimally invasive treatment method based on the interaction of light, photosensitizer (PS) and oxygen. In brain gliomas, iPDT involves stereotactic introduction one or more light guides into target area to irradiate tumor cells tissues that have accumulated PS, which subsequently causes necrosis and/or apoptosis cells, destruction vascular network an inflammatory reaction triggers stimulation antitumor immune response. The aim study was analyze possibility using in unifocal, small-sized (up 3.5 cm) glioblastomas. with included 7 patients unifocal variant glioblastoma maximum size up cm Karnofsky score at least 70 points. 5 (71.4%) there relapse glioblastoma, 2 cases (28.6%) diagnosed for first time. As PS photoditazine used, administered intravenously by drip dose 1 mg/kg. irradiation performed laser (Latus 2.5 (Atkus, Russia)) wavelength 662 nm power W cylindrical scattering fibers. volume determined after combining multimodal CT images (contrast-enhanced scanning, axial slices 0.6 mm) preoperative MRI, PET. Spatial precise interstitial planned special software. duration did not exceed 15 min. from 150 200 J/cm2. Transient clinical deterioration recorded about (28.6%). These had worsening neurological deficits early postoperative period (increase hemiparesis 4 points patient development dysarthria dysphasia second patient). median overall survival diagnosis malignant glioma death 28.3 months. relapse-free 13.1 MGMT status played significant role outcome treated iPDT. Patients methylated promoter survived longer than unmethylated 22.1 months, they experience disease progression additional 9.3 may be promising option population high risk deficit. It does interfere with, but rather complement, other options this disease, such as repeat radiation chemotherapy. remains potential deep-seated gliomas surgical case recurrence.

Language: Английский

Possibilities of interstitial photodynamic therapy in the treatment of brain glioblastoma DOI Creative Commons
A. Yu. Rynda,

V. E. Olyushin,

Д. М. Ростовцев

et al.

Biomedical Photonics, Journal Year: 2025, Volume and Issue: 14(1), P. 4 - 19

Published: April 16, 2025

Interstitial photodynamic therapy (iPDT) is a minimally invasive treatment method based on the interaction of light, photosensitizer (PS) and oxygen. In brain gliomas, iPDT involves stereotactic introduction one or more light guides into target area to irradiate tumor cells tissues that have accumulated PS, which subsequently causes necrosis and/or apoptosis cells, destruction vascular network an inflammatory reaction triggers stimulation antitumor immune response. The aim study was analyze possibility using in unifocal, small-sized (up 3.5 cm) glioblastomas. with included 7 patients unifocal variant glioblastoma maximum size up cm Karnofsky score at least 70 points. 5 (71.4%) there relapse glioblastoma, 2 cases (28.6%) diagnosed for first time. As PS photoditazine used, administered intravenously by drip dose 1 mg/kg. irradiation performed laser (Latus 2.5 (Atkus, Russia)) wavelength 662 nm power W cylindrical scattering fibers. volume determined after combining multimodal CT images (contrast-enhanced scanning, axial slices 0.6 mm) preoperative MRI, PET. Spatial precise interstitial planned special software. duration did not exceed 15 min. from 150 200 J/cm2. Transient clinical deterioration recorded about (28.6%). These had worsening neurological deficits early postoperative period (increase hemiparesis 4 points patient development dysarthria dysphasia second patient). median overall survival diagnosis malignant glioma death 28.3 months. relapse-free 13.1 MGMT status played significant role outcome treated iPDT. Patients methylated promoter survived longer than unmethylated 22.1 months, they experience disease progression additional 9.3 may be promising option population high risk deficit. It does interfere with, but rather complement, other options this disease, such as repeat radiation chemotherapy. remains potential deep-seated gliomas surgical case recurrence.

Language: Английский

Citations

0